Boundless Bio (BOLD) Other Non-Current Assets (2023 - 2026)
Boundless Bio (BOLD) posted quarterly Other Non-Current Assets of $560000.0 for Q1 2026, little changed year-over-year from $560000.0 in Q1 2025, and little changed quarter-over-quarter from $560000.0 in Q4 2025.
Boundless Bio (BOLD) Other Non-Current Assets (2023 - 2026) Analysis & Trends
Boundless Bio (BOLD) has reported Other Non-Current Assets for 4 consecutive years, with $560000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Assets changed 0.0% year-over-year to $560000.0; the TTM figure through Mar 2026 stood at $560000.0 (changed 0.0% YoY), while the FY2025 annual figure was $560000.0, up 465.66% from the prior year.
- Other Non-Current Assets was little changed at $560000.0 in Q1 2026 per BOLD's latest filing, from $560000.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $560000.0 in Q2 2023 and bottomed at $16000.0 in Q3 2024.
- Historically, Other Non-Current Assets has averaged $480615.4 across 4 years, with a median of $560000.0 in 2023.
- Annual changes were most pronounced in 2024 — Other Non-Current Assets tumbled 97.14% — and 2025, when it surged 3400.0%.
- Boundless Bio's Other Non-Current Assets stood at $560000.0 in 2023, then sank by 82.32% to $99000.0 in 2024, then soared by 465.66% to $560000.0 in 2025, then changed by 0.0% to $560000.0 in 2026.
- Business Quant data shows BOLD's Other Non-Current Assets at $560000.0 in Q1 2026, $560000.0 in Q4 2025, and $560000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.29 Bn | 132.43 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.58 Bn | 78.58 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.08 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 61.87 Bn | 56.73 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 42.18 Bn | 37.08 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.51 Bn | 28.20 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.90 Bn | 10.51 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.24 Bn | 26.41 Bn | - | 62.96 Mn |
| 10 | Boundless Bio | 66.79 Mn | 66.79 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 560,000.00 |
| Dec 31, 2025 | 560,000.00 |
| Sep 30, 2025 | 560,000.00 |
| Jun 30, 2025 | 560,000.00 |
| Mar 31, 2025 | 560,000.00 |
| Dec 31, 2024 | 99,000.00 |
| Sep 30, 2024 | 16,000.00 |
| Jun 30, 2024 | 560,000.00 |
| Mar 31, 2024 | 560,000.00 |
| Dec 31, 2023 | 560,000.00 |
| Sep 30, 2023 | 560,000.00 |
| Jun 30, 2023 | 560,000.00 |
| Mar 31, 2023 | 533,000.00 |